Purpose: Stenotrophomonas maltophilia, an uncommon cause of infectious keratitis, is difficult to treat because of its resistance to multiple antibiotics. The purpose of this study is to describe the clinical features, antibiotic susceptibility profile, and outcomes of S. maltophilia keratitis.
S
tenotrophomonas maltophilia is an aerobic, motile gramnegative bacillus that is ubiquitous in nature. 1 It has been isolated from plants, animals, soil, and even nutrient-poor aqueous environments. 2 In recent years, it has emerged as an opportunistic pathogen because of its intrinsic resistance to extended-spectrum cephalosporins, carbapenems, and aminoglycosides. 3 The inherent expression of at least 2 inducible b-lactamases is responsible for resistance of S. maltophilia to b-lactam agents and its high lethality rate among hospitalized patients. 4 S. maltophilia primarily causes infections in immunocompromised patients such as meningitis, endocarditis, upper respiratory tract infections, urinary tract infections, and skin/ soft tissue infections. 5 It is an uncommon keratitis pathogen with the total number of cases reported in the literature being less than 40. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The purpose of this study is to report the clinical characteristics, antibiotic susceptibilities, treatment course, and outcomes of culture-proven S. maltophilia infectious keratitis.
METHODS
A search of the database of the Ocular Microbiology Laboratory at the Bascom Palmer Eye Institute was performed for patients with corneal cultures positive for S. maltophilia between the years 1987 and 2016. Patient records were retrospectively reviewed for demographic information, medical and ocular history, systemic and local predisposing factors, presenting signs and symptoms, presenting and final visual acuity, treatment course, and outcomes. Corneal scrapings were routinely cultured on chocolate, 5% sheep blood, and Sabouraud with gentamicin agars, and thioglycolate broth. Plates were incubated in CO 2 (chocolate, blood, and thioglycolate) and/or non-CO 2 (Sabouraud) at 35°C for up to 7 days. Isolates were identified using Vitek 2 GramNegative Identification cards (BioMerieux, Durham, NC), commercial kits (API NE-nonfermeter Enterobacteriaceae -BioMerieux; Remel NF plus-nonfermenter, San Diego, CA), and/or conventional microbiologic procedures (aerobic/ anaerobic growth, oxidase, motility, and nitrate) by experienced laboratory personnel. A culture was considered positive if there was growth of more than 50 colonies on 1 solid medium (3+, heavy growth), 10 to 50 colonies on 2 or more media (2+, moderate growth), or 1 to 10 colonies on 1 solid medium and positivity on smears and/or thioglycolate broth (1+, light growth). Antimicrobial susceptibility was evaluated using a combination of disk diffusion, E-tests, and/or Vitek 2 Gram-Negative susceptibility cards. Results were interpreted according to the most current Clinical Laboratory Standards Institute guidelines.
This study was approved by the Institutional Review Board of the University of Miami Miller School of Medicine and complied with the principles outlined in the Declaration of Helsinki.
RESULTS
Twenty-six patients (58% women) with unilateral S. maltophilia keratitis were identified during the study period. The median follow-up time was 4.0 months (range, 1-120 mo).
Patient Demographics and Risk Factors
Median age at presentation was 64.9 years (range, . A total of 9 ulcers (34.6%) occurred in the right eye and 17 (65.4%) in the left eye. In 25 of the 26 patients, a risk factor for infectious keratitis was present; in 13 (50.0%) patients, there were multiple causes. Eight (30.8%) patients had a history of penetrating keratoplasty, and 9 patients (34.6%) were contact lens wearers. Three (11.5%) patients had a history of a nonhealing epithelial defect, 2 (7.7%) had recent surgery (EDTA chelation and laser in situ keratomileusis [LASIK]), 2 (7.7%) had a history of LASIK with evidence of epithelial ingrowth, 1 (3.8%) had a Boston keratoprosthesis and was on topical corticosteroids, and 1 (3.8%) had a history of trauma and was also HIV positive.
Microbiology and Antibiotic Susceptibilities
Light to moderate growth of isolates was recovered from 80% of patient samples. Isolates were identified using a combination of commercial kits (API NE, Rapid NF), Vitek 2 Gram-Negative Identification cards and/or supplementary conventional tests. Identification probabilities were accepted at 90% for Vitek or at least 85% for both commercial kit systems.
The antibiotic susceptibilities of the S. maltophilia isolates are summarized in Table 1 . In general, isolates were susceptible to the fluoroquinolones, with greater than 90% for both ciprofloxacin and levofloxacin. However, susceptibilities were less than 80% for polymyxin B and trimethoprim/ sulfamethoxazole (17/22; 77.3%). Only 35.7% of the tested isolates were susceptible to gentamicin, 33.3% to tobramycin, and 27.3% to amikacin. The susceptibility of the isolates to the cephalosporins was below 60%.
Concomitant pathogens (14/40, 35.0%) were recovered in 10 (38.5%) patients (see Table, Supplemental Digital Content 1, http://links.lww.com/ICO/A613, which reviews information on concomitant pathogens, treatment course, and outcomes for each patient included in this study). Three patients (30.0%) had multiple pathogens, whereas 7 (70.0%) had a single copathogen. Fifty-seven percent of the copathogens (8/14; 28.5% each) were recovered from contact lens wearers (4 copathogens) and patients with a history of penetrating keratoplasty (4 copathogens). One patient was both a contact lens wearer and had a history of penetrating keratoplasty. Multiple organisms were recovered from 1 patient with no identified risk factor. Most attendant pathogens were gram negative (7/14, 50.0%).
Clinical Presentation and Treatment
A summary of each patient's course is included in Supplemental Digital Content 1 (see Table, http:// links.lww.com/ICO/A613). The median time of the symptom duration before presentation was 5 days (range, 1-90 d). At presentation, 57.7% (15/26) of the patients had visual acuity of 20/400 or worse. In 19 (73%) patients, vision at presentation was 20/100 or worse. Sixteen (61.5%) patients had a central or paracentral infiltrate at presentation, and 5 (19.2%) had hypopyon. The initial empiric treatment was fortified vancomycin and tobramycin in 10 (38.5%) patients and fortified cefazolin and tobramycin in 5 (19.2%) patients. The addition of a fluoroquinolone or polymyxin B/trimethoprim was done for most of these patients once culture results were available (see Table, no change was made to the treatment regimen. Case 12 was lost to follow-up once empiric treatment was started. Cases 4 and 18 were improving clinically on the antibiotic regimen they were receiving-amikacin and tobramycin, respectively-and, thus, no change was made.
Clinical Outcomes
The treatment outcome for each patient is also shown in Supplemental Digital Content 1 (see Table, http://links.lww.com/ICO/A613). The median duration of treatment with antibiotics was 29 days (range, 4-105 d). At the final visit, only 30.4% (7/23) of the patients had visual acuity worse than 20/400, whereas 65.2% (15/23) of the patients had 20/100 or better. For 3 patients, final visual acuity was not available.
The corneal infection resolved with limited stromal scarring in 13 (50.0%) patients and with significant scarring and thinning in 5 (19.2%) patients. One patient (3.8%) with exposure keratopathy required tarsorrhaphy for the epithelial defect to heal. Two patients (7.7%) required therapeutic penetrating keratoplasty, 1 (3.8%) underwent enucleation of a painful blind eye with recurrence of the infection, and 1 (3.8%) underwent LASIK flap amputation. Three patients (11.5%) were lost to follow-up.
DISCUSSION
S. maltophilia has emerged as a global opportunistic pathogen responsible for multidrug-resistant nosocomial infections in debilitated hosts. 1 The prevalence rates of S. maltophilia from systemic sources have increased from 0.8% to 1.4% during 1997 to 2003 to 1.3% to 1.68% during 2007 to 2012. [17] [18] [19] [20] [21] [22] [23] Although the rate of systemic S. maltophilia infections has been slowly rising, the rate of S. maltophilia keratitis cases has remained stable at our institute for the periods 1987 to 2001 (6/774, 0.8%) and 2002 to 2016 (16/ 2475, 0.65%). The rate for the period 2015 to 2016 is 0.8% (4/503). S. maltophilia has also been reported to cause conjunctivitis, 24 endophthalmitis, 25 infantile dacryocystitis, 7 and preseptal cellulitis. 7 This study is the largest case series and review of culture-positive corneal ulcers caused by S. maltophilia. Almost half the patients (12/26; 46.2%) in our series were on chronic topical corticosteroids either because they had a history of penetrating keratoplasty (8/12; 66.7%) or a Boston keratoprosthesis (1/12; 8.3%) or because of recent ocular surgery (2/12; 16.7%) or recurrent ocular surface inflammation with a chronic nonhealing epithelial defect (1/12; 8.3%). In the second largest study to date on S. maltophilia keratitis, more than 75% of the patients (16/21) were on chronic corticosteroids because of a history of corneal graft surgery 26 and lens care systems, 27, 28 whereas its resistance to specific multipurpose disinfecting solutions has been well demonstrated in vitro. 28, 29 Sequencing of the S. maltophilia K279a genome revealed several genes that can explain the high-level resistance observed to a variety of chemically different antibiotics. 30 Intrinsic expression of b-lactamases, aminoglycosidemodifying enzymes, and multidrug-efflux pumps, the presence of a low-permeability outer membrane, and the capability of this bacterium to acquire additional resistance genes through incorporation of plasmid and transposon DNA render S. maltophilia immune to b-lactam antibiotics, aminoglycosides, quinolones, and disinfectants. 31, 32 Worldwide surveillance projects and multicenter studies on systemic infections show that the susceptibility of S. maltophilia to ceftazidime has decreased globally from 47% to 75% during 1997 to 1999 to 30.5% to 36.8% during 2009 to 2012. 17, 19, 33, 34 During the same period, susceptibility to trimethoprim/sulfamethoxazole remains stable with resistance rates that are generally less than 10%. 17, 19, [33] [34] [35] [36] [37] Sensitivity of S. maltophilia to levofloxacin has decreased from 83.4% during 2003 to 2008 to 77.3% in 2011. 17, 33 Nonetheless, 2 studies on moxifloxacin showed low MIC 50 (0.5 mg/L) and MIC 90 (8 and 4 mg/L) values, which suggests that moxifloxacin remains a good therapeutic option. 38, 39 In our series, only 33.3% of the tested isolates were sensitive to the aminoglycosides and 58.3% to the cephalosporins. This finding is consistent with the inherent resistance of S. maltophilia to these classes of antibiotic agents and to the global trend of decreasing susceptibility of S. maltophilia to cephalosporins. By contrast, all isolates except for 1 were sensitive to the fluoroquinolones and 72.2% of them were sensitive to trimethoprim/sulfamethoxazole. The single isolate that showed resistance to the fluoroquinolones was sensitive to polymyxin B. The respective patient who was initially on ofloxacin showed improvement once trimethoprim/polymyxin B was added to his treatment regimen. Similarly, in the study by Wu et al, all 21 S. maltophilia isolates were sensitive to the fluoroquinolones and 66.7% of them to trimethoprim/sulfamethoxazole.
All patients received medical therapy as per the culture results, and therapy was tapered off based on the clinical response. In 50% of them (n = 13), the infection did not result in significant stromal scarring or thinning. Nine of these 13 patients had received empiric antibiotic therapy (before the culture results) to which S. maltophilia was proven to be sensitive to. In 5 patients (19.2%), the infection resolved with topical antibiotics albeit with significant stromal scarring. Four patients (15.4%) required therapeutic surgery: penetrating keratoplasty (n = 2), LASIK flap amputation (n = 1), or enucleation (n = 1). Similarly, Wu et al 16 reported that close to one-fifth of their patients required therapeutic surgery for resolution of the infection, whereas in the others, S. maltophilia keratitis resolved with medical therapy alone.
Limitations of this study include its retrospective nature and its small sample size. Moreover, the presence of several polymicrobial cases is a well-known issue in any microbiological study and attests to the opportunistic nature of the organism and its affinity for compromised tissue. Although we cannot be sure that S. maltophilia was the main pathogen in each polymicrobial case, all patients responded well to the antibiotics to which S. maltophilia was shown to be susceptible in vitro. In the second largest study on S. maltophilia keratitis by Wu et al, 16 there were 12 polymicrobial cases (12/21; 57.1%) and in our series, 10 cases (10/26; 38.5%). The issue of colonization versus infection has been raised for systemic S. maltophilia infections as well. 3 In vitro studies have elucidated the role of S. maltophilia as an indirect pathogen in polymicrobial infections. b-lactamase leaking from S. maltophilia may encourage the growth of other b-lactam-susceptible gram-negative bacteria such as Serratia marcescens and Pseudomonas aeruginosa even in the presence of high levels of imipenem or ceftazidime. 40 We, thus, recommend treating S. maltophilia in polymicrobial ocular infections in patients with a compromised ocular surface.
Although related genetically to P. aeruginosa, infectious keratitis due to S. maltophilia is slowly progressive with smoldering symptoms. The patients in this study sought medical attention on average 14 days after their first symptoms. By contrast, patients with P. aeruginosa keratitis usually present much earlier due to rapid evolution of the disease process. 41 Future studies comparing S. maltophilia with a more common ocular pathogen, such as P. aeruginosa in terms of clinical signs and symptoms, antibiotic susceptibility profiles, and clinical outcomes, will enable better understanding of the pathogenicity of this peculiar organism. S. maltophilia keratitis should be suspected in any patient with a gram-negative infection in a compromised ocular surface who does not respond to fortified aminoglycosides or cephalosporin antibiotics. Fluoroquinolones and polymyxin/ trimethoprim are the treatment of choice for S. maltophilia infectious keratitis.
